Stockscreener 앱 받기
774.22
0.04%
0.275
전일 마감가:
$773.94
열려 있는:
$772
하루 거래량:
94,570
Relative Volume:
0.09
시가총액:
$81.36B
수익:
$14.25B
순이익/손실:
$4.58B
주가수익비율:
18.54
EPS:
41.7701
순현금흐름:
$3.88B
1주 성능:
-1.21%
1개월 성능:
-0.76%
6개월 성능:
+47.47%
1년 성능:
+8.69%
1일 변동 폭
$769.17
$774.56
1주일 범위
$769.17
$788.01
52주 변동 폭
$476.49
$792.77
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
774.16 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.19 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.79 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.20 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.93 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Simplify Asset Management Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rockland IDA votes to terminate and recapture Regeneron incentives - Westfair Communications
J&J Bispecific For Atopic Dermatitis Fails To Pass Muster - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Earnings Notes - Trefis
Cwm LLC Has $30.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) - Insider Monkey
Vontobel Holding Ltd. Has $5.83 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock split attract more investorsMarket Sentiment Shifts & High Return Capital Gain - bollywoodhelpline.com
Exchange Traded Concepts LLC Purchases 1,369 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Hunter Perkins Capital Management LLC - MarketBeat
Swedbank AB Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bar Harbor Wealth Management Purchases 3,304 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Brighton Jones LLC Buys 2,335 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
10 Best Debt Free Dividend Stocks to Buy Now - Insider Monkey
Does Regeneron Still Offer Value After Strong Five Year Share Price Gains? - Yahoo Finance
Sanofi Eczema Drug Linked To Lymphoma, Suit Says - Law360
Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year HighHere's What Happened - MarketBeat
Regeneron stock reaches 52-week high at $791.00 By Investing.com - Investing.com Australia
Regeneron stock reaches 52-week high at $791.00 - Investing.com
Regeneron Pharmaceuticals Stock (REGN) Opinions on Dupixent Success and Pipeline Developments - Quiver Quantitative
Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma (SNY:NASDAQ) - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma - The Manila Times
Regeneron and Sanofi Announce Approval of Dupixent® for Asthma Treatment in Children Aged 6 to 11 in Japan - Quiver Quantitative
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Diabetic Retinopathy Market to See Booming Growth 2025-2032 | - openPR.com
Aug Final Week: Will Regeneron Pharmaceuticals Inc. stock benefit from M&A activityJuly 2025 Snapshot & Safe Swing Trade Setups - moha.gov.vn
Wedge Capital Management L L P NC Buys New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc. - MarketBeat
Regeneron: The Turnaround Is Gaining Steam - Seeking Alpha
Published on: 2025-12-20 18:02:12 - Улправда
Voya Investment Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Corient Private Wealth LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Should Regeneron’s Clarified Eylea Biosimilar Timeline Reshape How REGN Investors View Its Core Franchise? - simplywall.st
Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06 - TipRanks
Published on: 2025-12-19 17:35:07 - Улправда
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stockSwing Trade & Daily Technical Forecast Reports - DonanımHaber
Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating - marketscreener.com
Texas Permanent School Fund Corp Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. (TEVA:NYSE) - Seeking Alpha
Alvotech and Teva Pharmaceuticals Announce Settlement Agreement with Regeneron for AVT06 Biosimilar Launch in the U.S. - Quiver Quantitative
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO |
Dec 09 '25 |
Option Exercise |
555.67 |
172,723 |
95,976,989 |
369,668 |
| LAROSA JOSEPH J | EVP General Counsel and Secret |
Nov 20 '25 |
Option Exercise |
555.67 |
14,450 |
8,029,431 |
35,525 |
| Bassler Bonnie L | Director |
Nov 20 '25 |
Option Exercise |
371.40 |
760 |
282,264 |
2,308 |
| Bassler Bonnie L | Director |
Nov 20 '25 |
Sale |
750.00 |
760 |
570,000 |
1,548 |
1.14%
0.05%
자본화:
|
볼륨(24시간):